Mutations in the p53 Gene in Lung Cancer are Associated with Cigarette Smoking and Asbestos Exposure

Cancer Epidemiology Biomarkers and Prevention

Volumn 4, Issue 5, 1995, Pages 543-548

  Wang, Xi ^a   Christiani, David C ^a,b   Wiencke, John K ^c   Fischbein, Michael ^b   Xu, Xiping ^a   Cheng, T J ^a   Mark, Eugene ^b   Wain, John C ^b   Kelsey, Karl T ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; ASBESTOS; CARCINOGEN; CIGARETTE SMOKE; CYTOSINE; GUANINE; OXYGEN RADICAL; PROTEIN P53; THYMINE;

ADULT; AGED; ARTICLE; CANCER RISK; CIGARETTE SMOKING; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RISK FACTOR; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

AGED; ASBESTOS; COMPARATIVE STUDY; FEMALE; GENES, P53; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGE; MUTATION; OCCUPATIONAL EXPOSURE; RISK FACTORS; SMOKING; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0029071344     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Knudson, A. G. Antioncogenes and human cancer. Proc. Natl. Acad. Sci. USA, 90: 10914–10921, 1993.
2. Mulshine, J. L., Treston, A. M., Brown, P. H., Birrer, M. J., and Shaw, G. L. Initiators and promoters of lung cancer. Chest, 103 (Suppl. 1): 4S–11S, 1993.
3. Levine, A. J., Chang, A., Dittmer, D., Notterman, D. A., Silver, A., Thom, K., Welsh, D., and Wu, M. The p53 tumor suppressor gene. J. Lab. Clin. Med., 123: 817–823, 1994.
4. Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. C. p53 mutations in human cancers. Science (Washington DC), 153: 49–53, 1991.
5. Caron de Fromentel, C., and Soussi, T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes & Cancer, 4: 1–15, 1992.
6. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318–1327, 1993.
7. Wynder, E. L., and Stellman, S. D. Impact of long-term filter use on lung and larynx cancer. J. Natl. Cancer Inst., 62: 471–477, 1979.
8. United States Department of Health, Education, and Welfare: Smoking and Health: A Report of the Surgeon General, Pub. No. 79. Washington DC: Department of Health, Education, and Welfare, 1979.
9. United States Department of Health and Human Services. The Consequences of Smoking. Cancer: A Report of the Surgeon General. Rockville, MD: Department of Health and Human Services, 1984.
10. Fielding, J. E. Smoking: health effects and control. N. Engl. J. Med., 313: 491–498, 1985.
11. Suzuki, H., Takahashi, T., Kuroishi, T., Suyama, M., Ariyoshi, Y., Taka-hashi, T., and Ueda, R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res., 52: 734–736, 1992.
12. Kazuya, K., Atsushi, U., Shigero, A., Tadashi, U., Kenshi, H., Yoshinari, O., and Yasumasa, M. Mutations in the p53 tumor suppressor gene in primary lung cancer in Japan. Biochem. Biophys. Res. Commun., 83: 1139–1146, 1992.
13. Chiba, I., Takahashi, T., Nau, M. M., D'Amico, D., Curiel, D. T., Mitsudomi, T., Buchhagen, D. L., Carbone, D., Piantadosi, S., Koga, H., Reissman, P. T., Slamon, D. J., Holmes, E. C., and Minna, J. D. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene, 5: 1603–1610, 1990.
14. Ryberg, D., Kure E., Lystad, S., Skaug, V., Stangeland, L., Mercy, I., Borresen, A-L., and Haugen, A. p53 mutations in lung tumors: relationship to putative susceptibility markers in cancer. Cancer Res., 54: 1551–1555, 1994.
15. Takeshima, Y., Seyama, T., Bennett, W. P., Akiyama, M., Tokuoka, S., Kouki, I., Mabuch, I. K., Land, C. E., and Harris, C. C. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet, 342: 1520–1521, 1993.
16. Takahashi, T., Suzuki, H., Hida, T., Sekido, Y., Ariyoshi, Y., and Ueda, R. The p53 gene is very frequently mutated in small-cell lung cancer with a distinct nucleotide substitution pattern. Oncogene, 6: 1775–1778, 1991.
17. Miller, C. W., Simon, K., Aslo, A., Kok, K., Yakota, J., Buys, C. H. C. M., Terada, M., and Koeffler, H. P. p53 mutations in human lung tumors. Cancer Res., 52: 1695–1698, 1992.
18. Kishimoto, Y., Murakami, Y., Shiraishi, M., Hayashi, K., and Sekiya, T. Aberrations of the p53 tumor suppressor gene in human non-small cell carcinomas of the lung. Cancer Res., 52: 4799–4804, 1992.
19. Mitsudomi, T., Oyama, T., Kusano, T., Osaki, T., Nakanishi, R., and Shirakusa, T. Mutations of the p53 gene as a predictor of poor prognosis in patients with non-small-cell lung cancer. J. Natl. Cancer Inst., 85: 2018–2023, 1993.
20. Taylor, J. A., Watson, M. A., Devereux, T. R., Michels, R. Y., Saccomano, G., and Anderson, M. p53 mutation hotspot in radon-associated lung cancer. Lancet, 343: 86–87, 1994.
21. Ruggeri, B., DiRado, M., Zhang, S. Y., Bauer, B., Goodrow, T., and Klein-Szanto, A. J. P. Benzo(a)pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc. Natl. Acad. Sci. USA, 90: 1013–1017, 1993.
22. Harris, C. C. At the crossroads of molecular carcinogenesis and risk assessment. Science (Washington DC), 262: 1980–1981, 1993.
23. Becklake, M. R. Asbestos-related diseases of the lung and pleura: current clinical issues. Am. Rev. Respir. Dis., 126: 187–194, 1982.
24. Lakowicz, J. R., Bevan, D. R., and Riemer, S. C. Transport of a carcinogen, benzo[a]pyrene, from particulates to lipid bilayers: a model for the fate of particle-adsorbed polynuclear aromatic hydrocarbons which are retained in the lungs. Biochim. Biophys. Acta, 629: 243–258, 1980.
25. Brown, R. C., Fleming, G. T., and Knight, A. I. Asbestos affects the in vitro uptake and detoxification of aromatic compounds. Environ. Health Perspect., 51: 315–318, 1983.
26. Menard, H., Noel, L., Khorami, J., Jouve, J. L., and Dunnigan, J. The adsorption of polyaromatic compounds on natural and chemically modified asbestos fibers. Environ. Res., 40: 84–91, 1986.
27. Kelsey, K. T., Yano, E., Liber, H. L., and Little, J. B. The in vitro genetic effects of fibrous erionite and crocidolite asbestos. Br. J. Cancer, 54: 107–114, 1986.
28. Hesterberg, T. W., and Barrett, J. C. Induction by asbestos fibers of anaphase abnormalities: mechanism for aneuploidy induction and possibly carcinogenesis. Carcinogenesis (Lond.), 6: 473–475, 1985.
29. Oshimura, M., Hesterberg, T. W., and Barrett, J. C. An early, nonrandom karyotypic change in immortal Syrian hamster cell lines transformed by asbestos: trisomy of chromosome 11. Cancer Genet. Cytogenet., 22: 225–237, 1986.
30. Willett, W. C., Sampson, L., Stampfer, M. J., Rosner, B., Bain, C., Witschi, J., Hennekens, C. H., and Speizer, F. E. Reproducibility and validity of a semiquantitative food frequency questionnaire. Am. J. Epidemiol., 122: 51–65, 1985.
31. Sprince, N. L., Oliver, L. C., McLoud, T. C., Eisen, E. A., Christiani, D. C., and Ginns, L. C. Asbestos exposure and asbestos-related pleural and parenchymal disease. Associations with immune imbalance. Am. Rev. Respir. Dis., 143: 822–828, 1991.
32. Toguchida, J., Yamaguchi, T., Richie, B., Beauchamp, R. L., Dayton, S. H., Herrera, G. E., Yamamuro, T., Kotoura, Y., Sasaki, M. S., Little, J. B., Weich-selbaum, R. R., Ishizaki, K., and Yandell, D. W. Mutation spectrum of the p53 gene in bone and soft tissue sarcoma. Cancer Res., 52: 6194–6199, 1992.
33. Maniatis, T., Fritsch, E. F., and Sambrook, J. Molecular Cloning: Analysis of Recombinant DNA Clones, pp. 368–369. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1986.
34. Nuorva, K., Soini, Y., Kamel, D., Autio-Harmainen, H., Risteli, L., Risteli, J., Vahakangas, K., and Paakko, P. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am. J. Pathol., 142: 725–732, 1993.
35. Gusterson, B. A., Anbazhagan, R., Warren, W., Midgely, C., Lane, D. P., O'Hare, M., Stamps, A., Carter, R., and Jayatilake, H. Expression of p53 in premalignant and malignant squamous epithelium. Oncogene, 6: 1785–1789, 1991.
36. Sundaresan, V., Ganly, P., Hasleton, P., Rudd, R., Sinhas, G., Bleehen, N. M., and Rabbitts, P. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumors, are detectable in preinvasive lesions of the bronchus. Oncogene, 7: 1989–1997, 1992.
37. Nuorva, K., Mäkitaro, R., Huhti, E., Kamel, D., Vähäkangas, K., Bloigu, R., Soini, Y., and Pääkkö, P. p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. Am. J. Respir. Crit. Care Med., 150: 528–533, 1994.
38. Hei, T. K., Piao, C. Q., He, Z. Y., Vannais, D., and Waldren, C. A. Chrysotile fiber is a strong mutagen in mammalian cells. Cancer Res., 52: 6305–6309, 1992.
39. Cote, R. J., Jhanwar, S. C., Novick, S., and Pellicer, A. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res., 51: 5410–5416, 1991.
40. Husgafvel-Pursiainen, K., Hackman, P., Ridanpaa, M., Antitila, S., Karjalainen, A., Partanen, T., Taikina-Aho, O., Heikkila, L., and Vainio, H. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int. J. Cancer, 53: 250–256, 1993.